PARTE A TRANSPORTER

Attorney Docket No. 1623-U-05

Application No.:09/966,311

Filing Date: 09/28/2001 Inventors: Berg, et al.

Group Art Unit: Examiner Name:

Attorney Docket No.: 1623-U-05

Information Disclosure Statement by Applicant

**U.S. PATENT DOCUMENTS** 

U.S. Department of Commerce Patent and Trademark Office

		<u>U.B.</u>	ALCINI	DOCUMENTS		
Examiner Initials*	Cite No.1	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
Ku		5,834,215		Garry et al.	11/10/1998	·
reco		5,846,758		Medenica	12/08/1998	
-						
· · · · · · · · · · · · · · · · · · ·						
			1			

**FOREIGN PATENT DOCUMENTS** 

Examiner Initials*	Cite No.1	Foreign Patent Document Office <sup>3</sup>	Foreign Patent Document Number <sup>4</sup>	Kind Code <sup>3</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

Examiner		Date	4
Signature	kutu	Considered	7/24/U3

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

			图	<u>6</u>	(
Form PTO-SB/08B	U.S. Department of Commerce Patent and Trademark Office	Application No.: Filing Date: Inventors: Senior et al.	TER 1600	1:5 2002	
Information Statement by		Group Art Unit: Examiner Name: Attorney Docket No.: 14	1600/2900 64-U-0		

Examiner nitials	Cite No. <sup>1</sup>	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
ke,		BERG, D. et al. Chronic Fatigue Syndrome and/or Fibromyalgia as a Variation of Antiphospholipid Antibody Syndrome: An Explanatory Model and Approach to Laboratory Diagnosis. Blood Coagulation and Fibrinolysis. October 1999, Vol. 10, No. 7, pages 435-438, see entire document.	
12.87		KAHN, S.R. et al. Nonvalvular Atrial Fibrillation: Evidence for a Prothrombic State. Can. Med. Assoc. J. September 1997, Vol. 157, No. 6, pages 673-681, see entire document.	
KS)		SAKATA, T. et al. Suppression of Plasma-Activated Facotr VII Levels by Warfarin Therapy.  Arterioscler. Thromb. Vasc. Biol. February 1995, Vol. 15, No. 2, pages 241-246, see entire document.	
1485		TAKAHASHI, H. et al. Evaluation of Oral Antigoagulant Therapy by Measuring Plasma Prothrombin Fragment 1 + 2. Blood Coagulation and Fibrinolysis. 1993, Vol. 4, No. 3, pages 435-439, see entire document.	
K 51		BERG, D.E. et al. Monitoring of Heparin Therapy by Soluble Fibrin Monomer (SFM) Levels in Infertile Women Who Became Pregnant and Carried Their Pregnancies to Full Term Delivery on Heparin: A comparison of Quantitative Versus Semiquantitative Methods for SFM. Blood. 1997, Vol. 90, No. 10, Suppl. 1, Part 2, page 111b. Abstract No. 3206.	<u></u>
<u>(</u> (5)		BONA, R. et al. Thrombin Generation and Activity are Increased in Patients with Cancer Receiving Sodium Warfarin as Secondary Prophylaxis Against Venous Thrombosis. Blood. 1997, Vol. 90, No. 10, Suppl. 1, Part 2, page 111b. Abstract No. 3207.	
Kiss		FON, E.A. et al. Hemostatic Markers in Acute Transient Ischemic Attacks. Stroke. February 1994, Vol. 25, No. 2, pages 282-286, see entire document.	
16		LIP, G.Y.H. et al. Increased Markers of Thrombogenesis in Chronic Atrial Fibrillation: Effects of Warfarin Treatment. British Heart Journal. 1995, Vol. 73, No. 6, pages 527-533, see entire document.	
1<5>		VECCHI, M. et al. Risk of Thromboembolic Complications in Patients with Inflammatory Bowel Disease. Int. J. Clin. Lab. Res. 1991, Vol. 21, No. 2, pages 165-170, see entire document.	
(ce)		The Merck Manual of Diagnosis and Therapy. 16 <sup>th</sup> Edition. Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ. Edited by: Berkow, R. et al. 1992, see pages 678-679.	
K85]		The Merck Manual of Diagnosis and Therapy. 16 <sup>th</sup> Edition. Merck Research Laboratories, Merck & Co., Inc., Rahway, NJ. Edited by: Berkow, R. et al. 1992, see pages 154-157, 841-845, 1312-1313, 1402-1407, 1488-1490, 1495-1500, 2102-2105, 2267-2268	
KS)		US 5,846,758 A (MEDENICA) 08 December 1998, see entire document.	
15)		US 5,834,215 A (GARRY et al.) 10 November 1998, see entire document.	

Examiner Signature Date Considered 7/24/03

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.



0

#### **COPY OF PAPERS ORIGINALLY FILED**

# Attorney Docket No. 1623 HECEIVED

JUL 22 2002

TECH CENTER 1600/2900

U.S. Department of Commerce Form PTO-SB/08B

Patent and Trademark Office

Application No.: Filing Date:

Inventors: David E. Berg et al..

**Information Disclosure** Statement by Applicant Group Art Unit: **Examiner Name:** 

Attorney Docket No.: 1623-U-05

O	THER	PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T²
اددا		BERG, D. et al, Identification of chronic fatigue syndrome (CFS) and Fibromyalgia (FM) as a Low Grade Hypercoagulable State: A Multi-Center, Blinded Random Study. Thrombosis and Haemostasis, Journal of the International Society on Thrombosis and Haemostasis, Abstracts, Supp. August 1999, page 317.	
······································			
_			
			-
Examine	т I	Date /	1 2
Signature	ş	Considered 7/24	درا

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.

BEST AND ABLE COPY



### RECEIVED

APR 1 0 2003

Attorney Docket No. 1623-U-05

## TECH CENTER 1600/2900

Form PTO-SB/08A

U.S. Department of Commerce

Patent and Trademark Office

Application No.:09/966,311

Filing Date: 09/28/2001 Inventors: Berg, et al.

Group Art Unit:

Examiner Name:

Attorney Docket No.: 1623-U-05

Information Disclosure Statement by Applicant

<u>O1</u>	THER P	RIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		- Mannucei, British Medical Bulletin 50(4): 851-870 (1994)	
Mile and an action of the	TO THE PROPERTY.	- Cohen et al., Am. J. Cardiol. 66(19): 1287=1292 (1990): Abstract.	

Examiner	16	Date	
Signature		Considered	<del>1</del> /241/7

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.

BEST AVAIL BLE COPY



# Attorney Docket No. 1623-U-05 ECEIVED

MAY 2 2 2003

Form PTO-SB/08A

U.S. Department of Commerce

Patent and Trademark Office

Application No.:09/966,31

Filing Date: 09/28/2001 Inventors: Berg, et al.

Group Art Unit: 1651

**Examiner Name:** 

Attorney Docket No.: 1623-U-05

Statement by Applicant

**U.S. PATENT DOCUMENTS** 

Examiner Initials*	Cite No.1	U.S. Patent Document Number	Kind Code <sup>2</sup> (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		4,451,454		Wong	05/29/1984	
		6,107,280		White et al.	08/22/2000	

Form PTO-SB/08A

U.S. Department of Commerce

Patent and Trademark Office

Application No.:09/966,311 Filing Date: 09/28/2001 Inventors: Berg, et al. Group Art Unit: 1651

**Information Disclosure** Statement by Applicant

**Information Disclosure** 

**Examiner Name:** 

Attorney Docket No.: 1623-U-05

<b>O</b> 7	THER !	PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T²
		BERG et al, Chronic fatigue syndrome and/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis. Blood Coagulation and Fibrinolysis 1999, Vol 10, No. 7, pgs. 435-438.	
		HANNAN et al., Activation of the coagulation system in Gulf War Illness: a potential pathophysiologic link with chronic fatigue syndrome - A laboratory approach to diagnosis. Blood Coagulation and Fibrinolysis 2000, Vol 11, No 7, pgs. 673-678.	
Examiner Signature		Date Considered	• .

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>Applicant is to place a check here if English language Translation is attached.

BES.

COPY
BEST AVAILABLE COPY